SCHEMBL6645478

SCHEMBL6645478

Cc1ccc(C(=O)Nc2ccc(NCCc3cccc(NC(=O)O)n3)cc2)c(N(C)C)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SORT1 Q99523 2/20 0.42
ALOX15 P16050 1/20 0.39
PLG P00747 3/20 0.38
KLK1 P06870 3/20 0.38
KLK6 Q92876 2/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
GRM5 P41594 1/20 0.38
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
GAA P10253 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C19 P33261 1/20 0.36
NPC1 O15118 3/20 0.36
RAB9A P51151 3/20 0.36
GBA1 P04062 1/20 0.36
TP53 P04637 1/20 0.36
MAPT P10636 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
CTNNB1 P35222 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6645269 0.88 PLG (0.42) ALOX15PLGKLK1KLK6MEN1
SCHEMBL6645991 0.86 CHRNB2 (0.44) SORT1NPC1RAB9AGBA1TP53
SCHEMBL6490949 0.85 GCGR (0.44) SORT1ALOX15PLGKLK1KLK6
SCHEMBL6647603 0.83 CTNNB1 (0.48) CYP3A4NPC1RAB9AMAPTSMN1; SMN2
SCHEMBL6645859 0.79 SMN1; SMN2 (0.40) ALOX15PLGKLK1KLK6MEN1
SCHEMBL6645440 0.78 KLKB1 (0.41) ALOX15MEN1KMT2AGAANPC1
SCHEMBL7134712 0.77 KMT2A (0.51) ALOX15PLGKLK1KLK6MEN1
SCHEMBL6645904 0.77 ITGB1 (0.43) SORT1TP53
SCHEMBL6646392 0.77 CTNNB1 (0.46) MEN1KMT2ACYP3A4GAANPC1
SCHEMBL6642315 0.76 TSHR (0.44) MEN1KMT2AGAANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040133008-A1 Amide compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-07-08 US disclosed
WO-2004039795-A2 AMIDE COMPOUNDS FOR THE TREATMENT OF HYPERLIPIDEMIA FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-05-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040133008-A1 Amide compounds APOB, APOL1, LDLR SORT1 1575/4885ALOX15 643/4885PLG 3968/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.